227. Osler disease Clinical trials / Disease details
Clinical trials : 54 / Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03910244 (ClinicalTrials.gov) | October 17, 2019 | 8/4/2019 | Pomalidomide for the Treatment of Bleeding in HHT | Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia | Telangiectasia, Hereditary Hemorrhagic | Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule | The Cleveland Clinic | RTI International | Recruiting | 18 Years | N/A | All | 159 | Phase 2 | United States |